Please use this identifier to cite or link to this item:
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/2454
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | PARDESHI, KUNDANSINGH A. | en_US |
dc.contributor.author | KUMAR, T. ANAND | en_US |
dc.contributor.author | RAVIKUMAR, GOVINDAN | en_US |
dc.contributor.author | Shukla, Manjulika | en_US |
dc.contributor.author | Kaul, Grace | en_US |
dc.contributor.author | Chopra, Sidharth | en_US |
dc.contributor.author | CHAKRAPANI, HARINATH | en_US |
dc.date.accessioned | 2019-04-25T07:00:12Z | |
dc.date.available | 2019-04-25T07:00:12Z | |
dc.date.issued | 2019-01 | en_US |
dc.identifier.citation | Bioconjugate Chemistry, 30(3), 751-759. | en_US |
dc.identifier.issn | 1043-1802 | en_US |
dc.identifier.uri | http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/2454 | - |
dc.identifier.uri | https://doi.org/10.1021/acs.bioconjchem.8b00887 | en_US |
dc.description.abstract | Fluoroquinolones (FQs) are among the front-line antibiotics used to treat severe infections caused by Gram-negative bacteria. However, recently, due to toxicity concerns, their use has been severely restricted. Hence, efforts to direct delivery of this antibiotic specifically to bacteria/site of infection are underway. Here, we report a strategy that uses a bacterial enzyme for activation of a prodrug to generate the active antibiotic. The ciprofloxacin-latent fluorophore conjugate 1, which is designed as a substrate for nitroreductase (NTR), a bacterial enzyme, was synthesized. Upon activation by NTR, release of Ciprofloxacin (CIP) as well as a fluorescence reporter was observed. We provide evidence for the prodrug permeating bacteria to generate a fluorescent signal and we found no evidence for activation in mammalian cells supporting selectivity of activation within bacteria. As a testament to its efficacy, 1 was found to have potent bactericidal activity nearly identical to CIP and significantly reduced the bacterial burden in a neutropenic mouse thigh infection model, again, at comparable potency with CIP, a clinically used FQ. Thus, together, we have developed a small molecule that facilitates bacteria-specific fluoroquinolone delivery. | en_US |
dc.language.iso | en | en_US |
dc.publisher | American Chemical Society | en_US |
dc.subject | Cephalosporin 3-Quinolone Esters | en_US |
dc.subject | Dual-Action Cephalosporins | en_US |
dc.subject | Controlled-Release | en_US |
dc.subject | Escherichia-Coli | en_US |
dc.subject | Sulfur-Dioxide | en_US |
dc.subject | Prodrug | en_US |
dc.subject | Fluoroquinolones | en_US |
dc.subject | Derivatives | en_US |
dc.subject | Design | en_US |
dc.subject | Antibiotics | en_US |
dc.subject | TOC-APR-2019 | en_US |
dc.subject | 2019 | en_US |
dc.title | Targeted Antibacterial Activity Guided by Bacteria-Specific Nitroreductase Catalytic Activation to Produce Ciprofloxacin | en_US |
dc.type | Article | en_US |
dc.contributor.department | Dept. of Chemistry | en_US |
dc.identifier.sourcetitle | Bioconjugate Chemistry | en_US |
dc.publication.originofpublisher | Foreign | en_US |
Appears in Collections: | JOURNAL ARTICLES |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.